Kumar Shiva Gubbiyappa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kumar Shiva Gubbiyappa has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Muthadi Radhika Reddy
Gitam School of Pharmacy, Gitam Deemed to be University, Hyderabad, India
2 shared publications - Anjaneyulu Patamsetti
GITAM Deemed to be University, India
1 shared publication Boddu Kishore Kumar
GITAM School of Pharmacy, GITAM Deemed to be University, 502329 Hyderabad, Telangana, India
1 shared publication
Latest Publications
- Open Access
- 7 May 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 383-389
PREPARATION, CHARACTERIZATION, AND IN VITRO ANTI CANCER ACTIVITY EVALUATION OF IRINOTECAN AND SUNITINIB-LOADED NANOBUBBLES
Objective: The objective of the present research is to develop, analyze, and evaluate the cytotoxic effects of nanobubbles loaded with irinotecan and sunitinib for colorectal cancer therapy. Methods: Drug-loaded dextran sulfate nanobubbles were formulated using the emulsification technique and the prepared nanobubbles were evaluated for qualitative and quantitative parameters. Cell viability MTT assay was performed to evaluate the irinotecan and sunitinib-loaded nanobubbles for cytotoxicity or ability to inhibit cell proliferation spectrophotometrically as a function of mitochondrial activity in living CR4 and A-549(irinotecan), CR4 and A-498 (sunitinib) cell lines. Results: The irinotecan and sunitinib-loaded nanobubbles were successfully prepared, with all qualitative and quantitative parameters within the acceptable range. The optimized nanobubbles demonstrated excellent physicochemical properties, with particle sizes of 177.8±5.2 nm for sunitinib and 89.8±9.5 nm for irinotecan. In vitro drug release studies showed significantly enhanced release profiles, with ultrasound-triggered drug release reaching 99% for both drugs, compared to only 39% for plain sunitinib and 35% for plain irinotecan. This highlights the ability of nanobubbles to enable controlled and targeted drug delivery, potentially improving therapeutic precision. The in vitro anticancer activity results revealed IC50 values of 70.41 and 73.26 µg/ml for irinotecan against CR4 and A-549 cell lines, respectively, and 84.34 and 60.08 µg/ml for sunitinib against CR4 and A-498 cell lines, respectively, demonstrating strong cytotoxic effects. Conclusion: The nanobubble-based delivery system enhances drug bioavailability, cellular uptake, and tumor penetration, thereby improving cytotoxic efficacy compared to conventional drug formulations. These findings underscore the potential of ultrasound-responsive nanobubbles as a promising strategy for targeted colorectal cancer therapy, potentially leading to improved treatment outcomes with reduced systemic toxicity.
- 7 May 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 383-389
Open AccessPREPARATION, CHARACTERIZATION, AND IN VITRO ANTI CANCER ACTIVITY EVALUATION OF IRINOTECAN AND SUNITINIB-LOADED NANOBUBBLES
Objective: The objective of the present research is to develop, analyze, and evaluate the cytotoxic effects of nanobubbles loaded with irinotecan and sunitinib for colorectal cancer therapy. Methods: Drug-loaded dextran sulfate nanobubbles were formulated using the emulsification technique and the prepared nanobubbles were evaluated for qualitative and quantitative parameters. Cell viability MTT assay was performed to evaluate the irinotecan and sunitinib-loaded nanobubbles for cytotoxicity or ability to inhibit cell proliferation spectrophotometrically as a function of mitochondrial activity in living CR4 and A-549(irinotecan), CR4 and A-498 (sunitinib) cell lines. Results: The irinotecan and sunitinib-loaded nanobubbles were successfully prepared, with all qualitative and quantitative parameters within the acceptable range. The optimized nanobubbles demonstrated excellent physicochemical properties, with particle sizes of 177.8±5.2 nm for sunitinib and 89.8±9.5 nm for irinotecan. In vitro drug release studies showed significantly enhanced release profiles, with ultrasound-triggered drug release reaching 99% for both drugs, compared to only 39% for plain sunitinib and 35% for plain irinotecan. This highlights the ability of nanobubbles to enable controlled and targeted drug delivery, potentially improving therapeutic precision. The in vitro anticancer activity results revealed IC50 values of 70.41 and 73.26 µg/ml for irinotecan against CR4 and A-549 cell lines, respectively, and 84.34 and 60.08 µg/ml for sunitinib against CR4 and A-498 cell lines, respectively, demonstrating strong cytotoxic effects. Conclusion: The nanobubble-based delivery system enhances drug bioavailability, cellular uptake, and tumor penetration, thereby improving cytotoxic efficacy compared to conventional drug formulations. These findings underscore the potential of ultrasound-responsive nanobubbles as a promising strategy for targeted colorectal cancer therapy, potentially leading to improved treatment outcomes with reduced systemic toxicity.
- 11 September 2024
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 83 (1) , 81-99
Development and characterization of palbociclib-loaded PLGA nanobubbles for targeted cancer therapy
- 11 September 2024
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 83 (1) , 81-99
Development and characterization of palbociclib-loaded PLGA nanobubbles for targeted cancer therapy
- 12 April 2023
- Published by Springer Nature in BioNanoScience
- Vol. 13 (2) , 521-540
Formulation Development, Optimization, and Characterization of Entrectinib-Loaded Supersaturable Self-Nanoemulsifying Drug Delivery Systems
- 12 April 2023
- Published by Springer Nature in BioNanoScience
- Vol. 13 (2) , 521-540
Formulation Development, Optimization, and Characterization of Entrectinib-Loaded Supersaturable Self-Nanoemulsifying Drug Delivery Systems
- Open Access
- 19 August 2022
- Published by Springer Nature in Research Square
Development of optimized self nano emulsifying systems of entrectinib for enhanced dissolution
Entrectinib is a novel potent anticancer drug with poor aqueous solubility. A supersaturable self nano emulsifying drug delivery system of entrectinib is developed using a super saturation promoter. The components of the isotropic mixture of SNEDDS were selected based on solubility and emulsification study. The optimum composition was identified using phase diagrams and further optimized by mixture design. The supersaturated SNEDDS was prepared using HPMC K4M as precipitation inhibitor. The droplet of sSNEDDS ranges from 118.42 ± 1.26 to 128.34 ± 0.63 nm with PDI values ranges from 0.112 to 0.204, which is significantly smaller than that observed with plain SNEDDS. The percent transmittance of the diluted formulation was found to be 98.78 ± 0.74. The viscosity was found to be 528 ± 32 centipoises indicating the good flow ability. FTIR and DSC studies indicated the amorphization of the drug. The dissolution profile of sSNEDDS indicated the faster release of drug compared to both pure drug suspension and SNEDDS formulation. The drug release rate is directly proportional to the concentration of the drug. The drug release from the insoluble matrix is a square root of time dependent Fickian diffusion process. The formulation was found to be stable and transparent at all pH values and the percent transmittance was more than 95%. No significant difference was observed with all the samples exposed at different storage conditions. This study demonstrated the feasibility of stabilizing and improving the in-vitro performance of SNEDDS by incorporating HPMC K4M as precipitation inhibitor.
- 19 August 2022
- Published by Springer Nature in Research Square
Open AccessDevelopment of optimized self nano emulsifying systems of entrectinib for enhanced dissolution
Entrectinib is a novel potent anticancer drug with poor aqueous solubility. A supersaturable self nano emulsifying drug delivery system of entrectinib is developed using a super saturation promoter. The components of the isotropic mixture of SNEDDS were selected based on solubility and emulsification study. The optimum composition was identified using phase diagrams and further optimized by mixture design. The supersaturated SNEDDS was prepared using HPMC K4M as precipitation inhibitor. The droplet of sSNEDDS ranges from 118.42 ± 1.26 to 128.34 ± 0.63 nm with PDI values ranges from 0.112 to 0.204, which is significantly smaller than that observed with plain SNEDDS. The percent transmittance of the diluted formulation was found to be 98.78 ± 0.74. The viscosity was found to be 528 ± 32 centipoises indicating the good flow ability. FTIR and DSC studies indicated the amorphization of the drug. The dissolution profile of sSNEDDS indicated the faster release of drug compared to both pure drug suspension and SNEDDS formulation. The drug release rate is directly proportional to the concentration of the drug. The drug release from the insoluble matrix is a square root of time dependent Fickian diffusion process. The formulation was found to be stable and transparent at all pH values and the percent transmittance was more than 95%. No significant difference was observed with all the samples exposed at different storage conditions. This study demonstrated the feasibility of stabilizing and improving the in-vitro performance of SNEDDS by incorporating HPMC K4M as precipitation inhibitor.